- Home
- MGNX vs NVNO Comparison
MGNX vs NVNO Comparison
Compare MGNX & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- NVNO
- Stock Information
- Founded
- MGNX 2000
- NVNO 1987
- Country
- MGNX United States
- NVNO United States
- Employees
- MGNX N/A
- NVNO N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- NVNO Medical/Dental Instruments
- Sector
- MGNX Health Care
- NVNO Health Care
- Exchange
- MGNX Nasdaq
- NVNO Nasdaq
- Market Cap
- MGNX 99.7M
- NVNO 96.0M
- IPO Year
- MGNX 2013
- NVNO N/A
- Fundamental
- Price
- MGNX $1.76
- NVNO $0.83
- Analyst Decision
- MGNX Hold
- NVNO
- Analyst Count
- MGNX 5
- NVNO 0
- Target Price
- MGNX $3.25
- NVNO N/A
- AVG Volume (30 Days)
- MGNX 582.9K
- NVNO 1.8M
- Earning Date
- MGNX 08-14-2025
- NVNO 07-31-2025
- Dividend Yield
- MGNX N/A
- NVNO N/A
- EPS Growth
- MGNX N/A
- NVNO N/A
- EPS
- MGNX N/A
- NVNO N/A
- Revenue
- MGNX $165,495,000.00
- NVNO N/A
- Revenue This Year
- MGNX N/A
- NVNO N/A
- Revenue Next Year
- MGNX N/A
- NVNO N/A
- P/E Ratio
- MGNX N/A
- NVNO N/A
- Revenue Growth
- MGNX 303.47
- NVNO N/A
- 52 Week Low
- MGNX $0.99
- NVNO $0.85
- 52 Week High
- MGNX $5.10
- NVNO $5.70
- Technical
- Relative Strength Index (RSI)
- MGNX 57.55
- NVNO 18.04
- Support Level
- MGNX $1.69
- NVNO $0.85
- Resistance Level
- MGNX $1.87
- NVNO $1.12
- Average True Range (ATR)
- MGNX 0.12
- NVNO 0.27
- MACD
- MGNX 0.02
- NVNO -0.32
- Stochastic Oscillator
- MGNX 71.59
- NVNO 0.14
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.